Sep 24 2025
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

DUBLIN, Sept. 22, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav^® (calcium, magnesium, potassium, and sodium oxybates) oral solution treatment outcomes in adults with narcolepsy or idiopathic hypersomnia (IH) were presented at World Sleep 2025, held in Singapore from September 5-10, 2025, as well as the 38^th annual Psych Congress, held in San Diego from September 17-21, 2025. Notable Phase 4 data included new results from the DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, showing treatment effects of low-sodium Xywav on daytime and nighttime symptoms of narcolepsy or IH. The DUET trial is a Phase 4, prospective, single-arm, open-label study to assess the effect of Xywav treatment on excessive daytime sleepiness, polysomnography parameters, and functional outcomes in adults with narcolepsy or IH.

Check out the full article here.